These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

958 related articles for article (PubMed ID: 29898844)

  • 21. A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.
    Gumprecht J; Domek M; Lip GYH
    Expert Opin Drug Saf; 2019 Dec; 18(12):1119-1125. PubMed ID: 31580164
    [No Abstract]   [Full Text] [Related]  

  • 22. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
    Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A
    Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
    Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.
    Matsumura-Nakano Y; Shizuta S; Komasa A; Morimoto T; Masuda H; Shiomi H; Goto K; Nakai K; Ogawa H; Kobori A; Kono Y; Kaitani K; Suwa S; Aoyama T; Takahashi M; Sasaki Y; Onishi Y; Mano T; Matsuda M; Motooka M; Tomita H; Inoko M; Wakeyama T; Hagiwara N; Tanabe K; Akao M; Miyauchi K; Yajima J; Hanaoka K; Morino Y; Ando K; Furukawa Y; Nakagawa Y; Nakao K; Kozuma K; Kadota K; Kimura K; Kawai K; Ueno T; Okumura K; Kimura T;
    Circulation; 2019 Jan; 139(5):604-616. PubMed ID: 30586700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
    Gong X; Hua R; Bai J; Wu T; Wang Q; Zhang J; Zhang W; Ying L; Ke Y; Wang X; Zhang X; Liu K; Chen Y; Zhang B; Dong P; Xiao J; Li C; Zhu L; Li C
    Clin Cardiol; 2023 Jul; 46(7):777-784. PubMed ID: 37191146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
    Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical appraisal of the AUGUSTUS trial.
    Gremmel T; Sulzgruber P; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):187-188. PubMed ID: 31265054
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry.
    Chandrasekhar J; Mastoris I; Baber U; Sartori S; Schoos M; Bansilal S; Dangas G; Mehran R
    Am Heart J; 2015 Dec; 170(6):1234-42. PubMed ID: 26678646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
    van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
    Trials; 2015 Sep; 16():393. PubMed ID: 26340977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
    Sindet-Pedersen C; Lamberts M; Staerk L; Nissen Bonde A; Berger JS; Pallisgaard JL; Lock Hansen M; Torp-Pedersen C; Gislason GH; Olesen JB
    J Am Coll Cardiol; 2018 Oct; 72(15):1790-1800. PubMed ID: 30286922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.